Banares J, Pons M, Reiberger T, Mandorfer M, Jachs M, Semmler G, Colecchia A, Colecchia L, Dajti E, Bureau C, Larrue H, Grgurevic I, Kujundzic PD, Fortea JI, Puente A, Berzigotti A, Tsochatzis E, Bosch J, Abraldes JG, Genesca J
Refining the Baveno VII criteria for clinically significant portal hypertension: an individual-patient data meta-analysis
J Hepatol. 2025 Oct 24:S0168-8278(25)02565-6
DOI: 10.1016/j.jhep.2025.10.014
IF: 48.5
RESEARCH GROUPS
Liver Diseases
79
Number of publications
78.48
%
% Q1
40.51
%
% D1
36.71
%
% Leadership
79.31
%
% Female Leadership
4.15
CROWN (2021-2025)
34.64
%
HCP10% (2021-2025)
77.22
%
% Open access
54.43
%
% International Collaboration
39
Highly cited papers / HCP 1% (2021-2025)
11
Publications in high-IF journals with high Altmetric scores
23
Number of Ongoing Projectes (total)
4
International ongoing projects
4
Number of New projects (total)
0
International new projects
49
Number of Active clinical Trials
8
Number of New Clinical Trials
1
Number of Theses
The Liver Diseases group is a reference in research in the liver diseases field at national and international levels. We are national leaders in clinical trials covering all the spectrum of liver diseases. Another essential feature of the group is the active contribution of our members to the most significant national and international medical societies of the liver field (Executive and Scientific Committees of AEEH, Governing Board of EASL). Additionally, we have been collaborating in international consortiums and projects funded by European institutions such as Decision, Artemis, among others.
CORE/MISSIONS
- AI, Data, Imaging & Digital Health
PROGRAMS
TEAM
Group Leader
Joan Genescà Ferrer
Principal Investigator (PI)
Maria Buti Ferret, Maria Martell Pérez-Alcalde, Beatriz Mínguez Rosique, Juan Manuel Pericàs Pulido, Josep Quer Sivila, Maria Del Mar Riveiro Barciela, Macarena Simon-Talero Horga, Meritxell Ventura Cots
Researchers
Lluis Castells Fusté, Isabel Campos Varela, Immaculada Raurell Saborit, David Tabernero Caellas, Mònica Pons Delgado, Jordi Llaneras Artigues, Adriana Palom Agusti, Mónica Higuera Urbano, Elena Vargas Accarino, Neda Akhlaghi, Sophia C. Parks
PhD Students
Ares Aurora Villagrasa Vilella, Marta Ibañez Lligoña, Maria Martínez Gómez, Sergi Colomer Castell, Carolina Campos Martinez, Juan Carlos Ruiz Cobo, Diego Rojo Lázaro, Alba Maria Jiménez Masip, Carlos Milton Cespedes Guachamboza, Laura Pagès Negre, Juan Bañares Sánchez, Maria Serra Cusidó Sabidó, Farnaz Faninam, Arnau Puitg Lopez, Agnes Soriano Varela, Alvaro González Camuesco
SELECTED PUBLICATIONS
Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, Chak E, Coffin CS, Fujiwara K, Gankina N, Gordon SC, Janczewska E, Komori A, Lampertico P, McPherson S, Morozov V, Plesniak R, Poulin S, Ryan P, Sagalova O, Sheng G, Voloshina N, Xie Q, Yim HJ, Dixon S, Paff M, Felton L, Lee M, Greene T, Lim J, Lakshminarayanan D, McGonagle G, Plein H, Youssef A, Elston R, Kendrick S, Theodore D
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
J Hepatol. 2025 Feb;82(2):222-234
DOI: 10.1016/j.jhep.2024.08.010
IF: 48.5
Buti M, Wedemeyer H, Aleman S, Chulanov V, Morozov V, Sagalova O, Stepanova T, Gish RG, Lloyd A, Kaushik AM, Suri V, Manuilov D, Osinusi AO, Flaherty JF, Lampertico P
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide
J Hepatol. 2025 Jan;82(1):28-36
DOI: 10.1016/j.jhep.2024.06.031
IF: 48.5
Aceituno L, Banares J, Pons M, Rivera-Esteban J, Sabiote C, Camma C, Ciancimino G, Pennisi G, Tulone A, Ma MM, Liu X, Watkins TR, Billin AN, Petta S, Pericas JM, Abraldes JG, Genesca J
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease
Gastroenterology. 2025 Nov 10:S0016-5085(25)05905-0
DOI: 10.1053/j.gastro.2025.08.020
IF: 25.9
Makary A, Rojo D, Pages L, Sabiote C, Jimenez-Masip A, Pericas JM
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
Hepatobiliary Surg Nutr. 2025 Oct 1;14(5):824-828
DOI: 10.21037/hbsn-2025-324
IF: 7.8
SELECTED PROJECTS
Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR)
Principal Investigator: Meritxell Ventura Cots/ Juan Manuel Pericàs
Agency: Instituto de Salud Carlos III
Funding: 183,920 €
Period: 01/01/2023 - 31/12/2026
Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular
Principal Investigator: Beatriz Minguez Rosique
Agency: Instituto de Salud Carlos III
Funding: 183,920 €
Period: 01/01/2022 - 31/12/2025
DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEM APPROACHES
Principal Investigator: Joan Genescà Ferrer
Agency: EUROPEAN COMMISSION
Funding: 130,472.5 €
Period: 01/04/2020 - 30/09/2026
ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients
Principal Investigator: José Raul Herance Camacho
Agency: EUROPEAN COMMISSION
Funding: 724,000 €
Period: 01/01/2024 - 31/12/2027
Búsqueda de biomarcadores (inmunológicos y/o celulares) predictivos de respuesta virológica o de control de la infección en la hepatitis crónica D
Principal Investigator: Maria Buti Ferret
Agency: Finançament: 220000
Funding: 220,000 €
Period: 01/01/2024 - 31/12/2026
PATENTS
DISSEMINATION ACTIVITIES
Liver Seminars 2025
Place: Barcelona
Date: 10 and 11/06/2025
Brief: The meetings served to share advances in translational research and consolidate international scientific alliances in the study of liver diseases
Update on screening and management of metabolic fatty liver disease in the outpatient setting
Place: VHIR
Date: 25/04/2025
Brief: The main aim of the day was to provide an update on the current state of knowledge and the importance attached to metabolic liver disease in the extra-hospital setting for a broad range of professionals.
